The American Society of Gene and Cell Therapy (ASGCT) defines cell therapy as a therapeutic modality that involves the administration of either normal or modified cells to patients for the treatment of various diseases. In this form of therapy, patients are injected with living and intact human cells that are deemed to be capable of providing therapeutic benefit. It is worth mentioning that such transplanted cells have been shown to restore or repair the cells that are damaged or have ceased functioning due to diseased condition. The main goal of cell therapy is to target the root cause of the disease at a cellular level. It is also worth highlighting that there are a significant number of cell therapies that are currently under clinical development.
Cell Therapy Manufacturers – Current Market Landscape
The current market landscape features the presence of over 240 CDMOs and in-house players that are engaged in the manufacturing of cell therapies, across various scales of operation
Want additional details on the database? It is just a click away.
Several industry players (XX) are actively contributing to the manufacturing and development of cell therapies in North America, Europe and Asia Pacific regions. We observed that the players are widely distributed across key geographical locations, with North America featuring the maximum number of facilities (XX), followed by Europe (XX) and Asia Pacific and MENA (XX).
The Increasing Interest in this Field is also Reflected in Recent Partnership Activity
The number of partnerships inked in this domain demonstrates the growing interest of players in the cell therapy manufacturing market; majority of the deals have been done for the clinical manufacturing of T cell therapies
Big Pharma Initiatives: Indicative of the Increasing Interest among Established Players
Around 50% of the big pharma initiatives have been undertaken for the purpose of expanding their portfolio and capabilities through partnerships and collaborations; of these, 70% initiatives were undertaken post 2019
Future Evolution of Cell Therapy Manufacturing Market
The global cell therapy manufacturing market is expected to grow at a CAGR of 12%, till 2035; T cell therapies and stem cell therapies capture more than 85% of the current market share
More than 1,000 cell and gene therapy candidates are currently being investigated for the treatment of a myriad of disease indications. In order to ensure the continued success of these novel therapies, there are several ongoing efforts to address the complexities related to their development and manufacturing. In recent years, several big pharma players have also undertaken initiatives, including establishing strategic partnerships with other industry players and carrying out expansion projects, in order to enhance their cell therapy manufacturing capabilities.
Considering the ongoing efforts of stakeholders to mitigate the manufacturing associated complications and an enhanced emphasis on the advancement of such therapies, the cellular therapy manufacturing market is anticipated to witness significant growth in the foreseen future.
For further information on this domain, check out the report –
Cell Therapy Manufacturing Market
You may also be interested in the following titles:
- Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (6th Edition), 2022-2035
- Cell and Gene Therapy CRO Market (3rd Edition), 2022-2035
- Gene Therapy Market (5th Edition), 2022-2035
- TIL-based Therapies Market, 2021-2030
- TCR-based Therapies Market, 2021-2030
Our Social Media Platform
- Web: https://www.rootsanalysis.com/
- LinkedIn: https://in.linkedin.com/company/roots-analysis
- Twitter: https://twitter.com/RootsAnalysis
The post Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders appeared first on Blog.